You are here: Industry Insights > cancer

News List

Lantern Pharma Launches ADC Program contractpharma
January 05, 2021
?Lantern Pharma, a clinical-stage biopharma company using its RADR artificial intelligence platform to advance cancer drug development, is launching the development of its ADC (Antibody Drug Conjugate) program through an evaluation and potential ...
Tel Aviv University develops novel lipid nanoparticle-based delivery system to destroy cancer cells expresspharma
January 05, 2021
The system, called CRISPR-LNPs, carries a genetic messenger (messenger RNA), which encodes for the CRISPR enzyme Cas9 that acts as molecular scissors that cut the cells’ DNA.
Hoth Therapeutics Announces Production of HT-001 for Cancer Treatment prnewswire
January 04, 2021
Hoth Therapeutics, Inc., a biopharmaceutical company, announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001 with Tergus Pharma for its novel cancer treatment drug, HT-001.
Concord Medical Announces Divestment of Singapore Concord International Hospital prnasia
December 29, 2020
Concord Medical Services Holdings Limited, a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers...
Innovent Announces the NMPA Granted New Indication Approval for BYVASDA? (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma prnasia
December 28, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces that BYVASDA? ...
Senhwa Biosciences Receives US FDA 'Study May Proceed' Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461 prnasia
December 24, 2020
Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announced that it has received a "Study May Proceed" letter from the US Food and Drug ...
FDA grants priority review to KEYTRUDA for treatment of esophageal and gastroesophageal junction cancer pharmaceutical-business-review
December 22, 2020
Merck announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum and ...
BioEclipse Initiates Enrollment in Phase 1 Dose-Escalation Trial for Solid Tumors americanpharmaceuticalreview
December 22, 2020
BioEclipse Therapeutics? announced the initiation of patient enrollment in a Phase 1 dose-escalation trial to treat refractory solid tumors.
ICR scientists create 3D protein structure for new therapy development pharmaceutical-technology
December 21, 2020
The UK Institute of Cancer Research, London (ICR) researchers have created a three-dimensional (3D) structure of a complex of molecules for new therapies.
Varian and Yonsei Cancer Center, Yonsei University Health System Sign MOU to Further Innovation to Treat Cancer Patients prnasia
December 16, 2020
Varian today announced that it has entered into a three-year agreement with Yonsei Cancer Center, Yonsei University Health System to collaborate on research and development projects in the field of radiation therapy and oncology.